XBiotech Inc (XBIT) ニュース

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is...

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

0001626878 false 0001626878 2023-06-23 2023-06-23 iso4217:USD xbrli:shares...

Amended Tender Offer Statement by Issuer (sc To-i/a)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE TO Tender Offer...

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s...

Tender Offer Statement by Issuer (sc To-i)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE TO Tender Offer...

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch...

Quarterly Report (10-q)

0001626878 XBiotech Inc. false --12-31 Q1 2023 0 0 Unlimited Unlimited 0 0 0 0 Unlimited Unlimited 30,439,275 30,439,275 30,439...

Annual Report to Security Holders (ars)